Dermatomyositis Market Outlook 2032 | Priovant Therapeutics, CSL Behring, Alexion Pharmaceuticals, AstraZeneca, Argenx, Pfizer, Janssen

Dermatomyositis Market Outlook 2032 | Priovant Therapeutics, CSL Behring, Alexion Pharmaceuticals, AstraZeneca, Argenx, Pfizer, Janssen
Dermatomyositis Market
Nonpharmacological therapies, like exercise and physical therapy, are essential to managing dermatomyositis. It helps improve muscle strength, mobility, and function.

DelveInsight’s “Dermatomyositis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dermatomyositis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Dermatomyositis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Dermatomyositis Overview

Dermatomyositis is a rare autoimmune disease characterized by muscle weakness and skin rash. Here’s an overview of its causes, symptoms, diagnosis, and treatment:

Dermatomyositis Causes:

The exact cause of dermatomyositis is unknown, but it is believed to involve a combination of genetic predisposition, environmental triggers, and autoimmune factors. In some cases, it may be associated with certain cancers, such as ovarian, lung, or gastrointestinal cancers, although this link is not fully understood.

Dermatomyositis Symptoms:

  • Muscle Weakness: Symmetrical muscle weakness, typically affecting the muscles closest to the trunk, such as those in the hips, thighs, shoulders, and upper arms. Weakness may progress gradually over weeks to months.
  • Skin Rash: Characteristic skin rash, often seen as a reddish-purple discoloration, typically on the face, eyelids, knuckles, elbows, knees, or chest. This rash may be accompanied by swelling and tenderness.
  • Fatigue: Generalized fatigue and malaise, which may be severe and debilitating.
  • Difficulty Swallowing: Weakness in the muscles involved in swallowing, leading to difficulty swallowing (dysphagia).
  • Joint Pain: Joint pain and inflammation, particularly in the wrists, fingers, and knees.
  • Other Symptoms: Additional symptoms may include fever, weight loss, lung inflammation (interstitial lung disease), and inflammation of the blood vessels (vasculitis).

Dermatomyositis Diagnosis:

Diagnosing dermatomyositis involves a combination of clinical evaluation, blood tests, imaging studies, and sometimes muscle biopsy. Key diagnostic tests include:

  • Blood Tests: To check for elevated levels of muscle enzymes (creatine kinase, aldolase) and autoantibodies associated with dermatomyositis, such as anti-Jo-1 and anti-Mi-2 antibodies.
  • Muscle Biopsy: Removal and microscopic examination of a small sample of muscle tissue to look for characteristic changes, such as inflammation and muscle fiber damage.
  • Imaging Studies: MRI or CT scans may be performed to assess muscle inflammation and detect abnormalities.

Dermatomyositis Treatment Market:

Treatment for dermatomyositis aims to relieve symptoms, suppress inflammation, and prevent complications. It typically involves a combination of medications and supportive therapies:

  • Corticosteroids: High-dose corticosteroids, such as prednisone, are usually the first-line treatment to reduce inflammation and improve muscle strength.
  • Immunosuppressants: Additional medications, such as methotrexate, azathioprine, mycophenolate, or rituximab, may be used to help reduce the need for high-dose steroids and control autoimmune activity.
  • Physical Therapy: Rehabilitation exercises and physical therapy can help maintain muscle strength, flexibility, and function.
  • Sun Protection: Sunscreen and protective clothing are important to prevent skin rash exacerbations triggered by sun exposure.
  • Treatment of Complications: Complications such as lung inflammation or swallowing difficulties may require additional treatments tailored to the specific symptoms.

Dermatomyositis Market Key Facts

  • In 2021, the total Dermatomyositis market size was ~USD 180 million in the 7MM, which is expected to rise during the study period.
  • The total Dermatomyositis market size in the United States was ~USD 130 million in 2021.
  • In 2021, the total Dermatomyositis prevalent case was ~61,200 cases in the 7MM, which are expected to grow by 2032.
  • As per DelveInsight’s estimates, in the 7MM, the highest number of total prevalent cases of Dermatomyositis were observed in the United States, with ~35,300 cases in 2021, estimated to increase by 2032 at a moderate CAGR.
  • The total prevalent cases of Dermatomyositis in EU4 and the UK comprised ~18,000 cases in 2021 and are projected to increase by 2032 at a moderate CAGR during the forecast period.

Dermatomyositis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Dermatomyositis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Dermatomyositis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Dermatomyositis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Dermatomyositis Epidemiology, Segmented by –

  • Total Prevalent Cases of Dermatomyositis 
  • Total Diagnosed Prevalent Cases of Dermatomyositis 
  • Gender-specific Diagnosed Prevalent Cases of Dermatomyositis 
  • Age-specific Diagnosed Prevalent Cases of Dermatomyositis 
  • Severity-specific Diagnosed Prevalent Cases of Dermatomyositis 
  • Classification-Specific Diagnosed Prevalent Cases of Dermatomyositis 
  • Chronicity-Specific Diagnosed Prevalent Cases of Dermatomyositis 
  • Co-morbidity-Specific Diagnosed Prevalent Cases of Dermatomyositis 
  • Treated cases of Dermatomyositis

Dermatomyositis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dermatomyositis market or expected to be launched during the study period. The analysis covers the Dermatomyositis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dermatomyositis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Dermatomyositis Market Will Evolve and Grow by 2032 @

Dermatomyositis Therapeutics Analysis

The objective of treatment aims to lessen inflammation and vasculitis, consistently alleviating symptoms and enhancing the patient’s quality of life. To attain this objective, early initiation of a treatment regimen is crucial, necessitating a collaborative approach among healthcare professionals. Managing Dermatomyositis entails the use of steroid administration, with early initiation of high-dose prednisolone to address muscle weakness. Moreover, on a global scale, numerous prominent companies are actively engaged in advancing therapeutics for Dermatomyositis treatment.

Leading Companies in the Dermatomyositis Therapeutics Market Include:

  • Priovant Therapeutics
  • CSL Behring
  • Alexion Pharmaceuticals
  • AstraZeneca
  • Argenx
  • Pfizer
  • Janssen
  • And Many Others

Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Contents

1. Key Insights

2. Executive Summary 

3. Dermatomyositis Competitive Intelligence Analysis

4. Dermatomyositis Market Overview at a Glance

5. Dermatomyositis Disease Background and Overview

6. Dermatomyositis Patient Journey

7. Dermatomyositis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Dermatomyositis Treatment Algorithm, Current Treatment, and Medical Practices

9. Dermatomyositis Unmet Needs

10. Key Endpoints of Dermatomyositis Treatment

11. Dermatomyositis Marketed Products

12. Dermatomyositis Emerging Drugs and Latest Therapeutic Advances

13. Dermatomyositis Seven Major Market Analysis

14. Attribute Analysis

15. Dermatomyositis Market Outlook (In US, EU5, and Japan)

16. Dermatomyositis Access and Reimbursement Overview

17. KOL Views on the Dermatomyositis Market

18. Dermatomyositis Market Drivers

19. Dermatomyositis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States